 UniQure NV NASDAQ: QURE shares were advancing to four-month highs Thursday in reaction to a positive clinical data readout. What Happened: The Lexington, Massachusetts-based company announced positive top-line data from a pivotal Phase 3 study, dubbed HOPE-B, that evaluated its investigational adeno-associated virus five-based gene-therapy candidate etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B. 